Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2017 Type 1 diabetes mellitus (T1DM) affects 345,000 children and adults in the UK and a proportion of these patients develop hypoglycaemia unawareness. This often results in life-threatening episodes of severe hypoglycaemia. Transplantation of isolated islets of Langerhans is a minimally invasive procedure that can restore hypoglycaemia awareness in the majority of patients and has huge potential for reversing T1DM. However, it is not currently available for treating children due to the requirement for life-long immunosuppression. This review will focus on the current practice of islet transplantation in the UK, as well as the challenges and recent developments in the field. These include optimising pancreas procurement and islet isolation, improving post-transplant islet engraftment and survival, and the use of renewable sources of islets such as stem cells. It will also discuss the novel strategies being developed to enable immunosuppression-free islet transplantation. The ultimate aim is to be able to offer this technology to young people soon after diagnosis, and thereby provide a safe and sustainable “cure” for T1DM.

Original publication




Journal article


Paediatrics and Child Health (United Kingdom)

Publication Date





181 - 186